# ERK Inhibitor JSI-1187 in Advanced Solid Tumors

> **NCT06239623** · PHASE1 · UNKNOWN · sponsor: **JS InnoPharm, LLC** · enrollment: 60 (estimated)

## Conditions studied

- Solid Tumor
- NSCLC
- Melanoma

## Interventions

- **DRUG:** JSI-1187

## Key facts

- **NCT ID:** NCT06239623
- **Lead sponsor:** JS InnoPharm, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-02
- **Primary completion:** 2024-09-28
- **Final completion:** 2024-12-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06239623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06239623, "ERK Inhibitor JSI-1187 in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06239623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*